Reuters covered the Nasdaq debut of Medtronic's diabetes unit, MiniMed, which opened below its offer price amid heightened market volatility. The $5.35 billion listing highlights ongoing challenges in the new issues market. IPOX® Research Associate Lukas Muehlbauer provided expert commentary on the debut, noting that while the offering "shows that the U.S. IPO market is still open," current economic conditions clearly dictate "that it has become a price-sensitive buyers' market."

A recent Bloomberg article highlights the massive outperformance of European defense and aerospace IPOs, which have averaged 87% gains since 2020. Driven by geopolitical tensions and NATO rearmament, this surge in investor demand is prompting a fresh wave of public listings. IPOX® Research Analyst Lukas Muehlbauer provided expert commentary, explaining that ongoing conflicts have created unprecedented backlogs, making IPOs a practical way for defense firms to raise cash and expand capacity.

Reuters highlights SoftBank-backed PayPay’s upcoming $13.4 billion U.S. IPO, a highly anticipated offering expected to boost a volatile listing market. Discussing current market dynamics, IPOX® CEO Josef Schuster noted robust investor appetite is particularly strong for specialty firms across healthcare and select fintech that are insulated from geopolitical and AI-related risks.

Elon Musk’s SpaceX is reportedly preparing to confidentially file for a U.S. initial public offering as early as March, aiming for a record-breaking June listing. This highly anticipated share sale could raise up to $50 billion and command a staggering valuation exceeding $1.75 trillion, bolstered by its recent acquisition of the artificial intelligence startup xAI. SpaceX has already aligned major financial institutions, including Bank of America, Goldman Sachs, JPMorgan, and Morgan Stanley, to lead this historic, market-defining public market debut.

A recent Reuters article highlights Medtronic’s plan to spin off its diabetes unit, MiniMed, targeting a $7.9 billion valuation in its upcoming U.S. IPO. Seeking to raise up to $784 million, the move allows Medtronic to focus on high-margin growth markets. IPOX® Research Associate Lukas Muehlbauer provided expert commentary on the spin-off, noting that while MiniMed offers investors pure-play exposure to diabetes technology as an established business, its recent net losses mean investors will demand a clear path to profitability.

Reuters highlights Generate Biomedicines' upcoming U.S. IPO, targeting a $2.17 billion valuation. As the biotech IPO market resurges, the firm aims to raise $425 million for its AI-driven drug discovery pipeline. IPOX® Research Associate Lukas Muehlbauer provided expert commentary, noting that Generate's institutional backing and pharma partnerships offer significant credibility. However, he emphasized that investors will closely scrutinize the platform's valuation, demanding clear proof of its AI capabilities.

The U.S. IPO market faces headwinds as Clear Street and Liftoff Mobile withdraw their listings. IPOX® Associate Lukas Muehlbauer and IPOX® VP Kat Liu noted that AI-driven volatility and crypto declines forced these moves to avoid "failed" IPO stigmas. Meanwhile, Bain Capital explores a $3 billion IPO for Dessert Holdings. In Europe, Thyssenkrupp plans a $13.5 billion materials spin-off, while UI Boustead REIT preps a $788 million Singapore float.

Reuters reports that Wall Street broker Clear Street has withdrawn its U.S. IPO amid market volatility and AI disruption fears. The withdrawal highlights ongoing challenges for fintech firms navigating weak sector sentiment. IPOX® VP Kat Liu provided expert commentary, noting the risks of forcing a poorly received offering. "If demand wasn't there even at a severe discount, pushing through a weakly received deal would have risked the stigma of a 'failed' IPO," Liu explained

A recent Bloomberg article notes that while recent European stock debuts face market pressure, traditional sectors like banking and energy demonstrate strong resilience. Amid a slow market for follow-on offerings, IPOX® Research Associate Lukas Muehlbauer commented on the challenges of underwater stocks.

A recent Reuters article highlights Blackstone-backed Liftoff Mobile's decision to withdraw its U.S. IPO amid a sharp software sector selloff. This sudden delay reflects broader market volatility driven by rapid AI advancements threatening established economic moats. IPOX® Research Associate Lukas Muehlbauer provided expert commentary on the situation, noting that private equity sponsors prefer withdrawing over accepting deeply disappointing valuations. Muehlbauer emphasized that current investor skepticism is a healthy sign of a disciplined market, preventing overheating and benefiting long-term pipeline stability.

ARKO Petroleum’s recent Nasdaq debut, valued at $808 million, saw shares slip 1.4% amid heightened market volatility. IPOX® VP Kat Liu provided expert analysis on the cautious investor sentiment surrounding 2026 listings. "In the current environment, where volatility remains elevated and many IPOs have struggled to hold above their offer price, investors are definitely approaching deals with caution," Liu noted, highlighting the growing scrutiny facing new stocks in today's shifting financial landscape.

Goldman Sachs predicts a historic $160 billion U.S. IPO boom in 2026, though market volatility is currently testing recent listings. ARKO Petroleum debuted softly at an $808 million valuation, with IPOX® VP Kat Liu noting investors are "approaching deals with caution." Consequently, Clear Street and Agibank recently downsized or postponed their offerings. Globally, mega-deals continue to advance as DayOne targets a $20 billion U.S. listing and PayPay files for $1.5 billion. Meanwhile, IPOX® Associate Lukas Muehlbauer warns of volatility risks amid Saudi Arabia’s retail IPO push.

A Reuters article details Wall Street broker Clear Street’s decision to slash its IPO fundraising target by 65% amid investor caution. IPOX® Research Associate Lukas Muehlbauer provided expert commentary, noting that recent volatility in AI-driven financial stocks and sharp declines in crypto markets likely dampened sentiment, given Clear Street's exposure to crypto treasury capital raises. The move reflects a broader trend of demanding realistic pricing for new listings.

Agibank slashed its U.S. IPO size by over 50% and lowered its price range following the poor aftermarket performance of rival PicPay. Reuters featured IPOX® Research Associate Lukas Muehlbauer, who analyzed the valuation pressures facing the Brazilian fintech. Muehlbauer noted that while the restructured deal, now consisting solely of primary shares, allows the listing to proceed, it introduces potential stock overhang risks as existing shareholders chose to retain their positions rather than sell at lower valuations.

A recent Bloomberg article highlights the debate over Saudi Arabia’s push to increase retail IPO allocations to 30%. IPOX® Associate Muehlbauer is featured, noting that high retail quotas in a recovering market may force issuers to offer steeper discounts. This post includes Muehlbauer's full commentary to Bloomberg, discussing global parallels with India’s model and the potential for these allocations to serve as "citizen dividends," while cautioning against short-term volatility risks.